Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.40 |
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.32 |
| ▸ | HPD | P32754 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931300 | 0.87 | HSP90AA1 (0.41) | HSP90AA1ESR1ESR2 | |
| SCHEMBL13983074 | 0.86 | HSP90AA1 (0.41) | HSP90AA1ESR1ESR2MAOAMAOB | |
| SCHEMBL930546 | 0.85 | HSP90AA1 (0.40) | HSP90AA1ESR1ESR2PDK1PDK2 | |
| SCHEMBL931880 | 0.83 | HSP90AA1 (0.57) | HSP90AA1ESR2MAOAMAOB | |
| SCHEMBL930234 | 0.81 | MAOA (0.38) | HSP90AA1ESR1AMY1AMAOAMAOB | |
| SCHEMBL4933223 | 0.80 | HSP90AA1 (0.57) | HSP90AA1ESR1MAOB | |
| SCHEMBL931738 | 0.79 | NPC1 (0.40) | HSP90AA1ESR1 | |
| SCHEMBL931649 | 0.78 | HSP90AA1 (0.46) | HSP90AA1MAOAMAOB | |
| SCHEMBL932177 | 0.78 | ESR1 (0.48) | HSP90AA1ESR1ESR2AMY1ARXRA | |
| SCHEMBL931653 | 0.76 | GAA (0.45) | HSP90AA1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295416-A2 | Triazole compounds that modulate HSP90 activity | Synta Pharmaceuticals Corp. (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2298748-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2298748-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9090569-B2 | Triazone compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2007139951-A9 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH PROTOONCOGENE PRODUCTS | SYNTA PHARMACEUTICALS CORP (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| WO-2007139960-A2 | COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139951-A2 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH PROTOONCOGENE PRODUCTS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885ESR1 4584/4885ESR2 3439/4885 |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | HSP90AB1, HSP90B1, CDC37 | HSP90AA1 4/4885ESR1 3143/4885ESR2 2914/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885ESR1 1794/4885ESR2 1563/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885ESR1 3993/4885ESR2 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.